Story
Stokke Industri Explores Sale of Jets AS in Potential $525 Million Deal
Summary
Family-backed investment firm Stokke Industri is reportedly working with Citigroup to evaluate a sale of its majority stake in Norwegian sanitation technology company Jets AS, a transaction that could value the business at approximately $525 million.
Stokke Industri, the investment firm for the family behind the Stokke children's furniture brand, is exploring a potential sale of its stake in Norwegian sanitation systems manufacturer Jets AS. The deal could value the specialized technology company at approximately 5 billion kroner ($525 million), according to a Bloomberg report citing people familiar with the matter.
Potential Transaction
The family-backed investment firm is reportedly working with advisers at Citigroup Inc. to gauge interest from potential buyers for its 73% stake in Jets AS. The sources indicated that deliberations are in the early stages and there is no certainty that a sale will ultimately occur.
Market observers anticipate interest could come from both private equity firms and strategic industrial buyers. A divestment would represent a significant monetization event for Stokke Industri.
Profile of Jets AS
AdBased in Hareid, Norway, Jets AS is a specialized provider of vacuum toilets and advanced wastewater treatment infrastructure. The company's technology is primarily used in marine vessels and commercial buildings.
According to the report, Jets AS has a strong financial profile, generating approximately:
- 1 billion kroner in revenue in 2025
- 300 million kroner in earnings in 2025
This performance highlights the high-margin nature of the sanitation technology sector in which the company operates.
Read next
More on Stocks
Brazil's Bovespa Index Gains 0.46% on Sector Strength Despite Rising Volatility
Brazil's benchmark stock index closed higher on Tuesday, supported by gains in the real estate and financial sectors, even as an index measuring market volatility surged to a three-year high.
4D Molecular Therapeutics Named Top Biotech Pick by B. Riley on Gene Therapy Promise
B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a key Phase 3 trial and promising long-term data for its eye disease gene therapy, 4D-150.
S&P Upgrades Wells Fargo to 'A-' on Risk Management Progress
S&P Global Ratings has raised Wells Fargo's long-term credit rating, citing significant improvements in governance and risk oversight following the removal of a long-standing Federal Reserve asset cap.
Evercore ISI Names Top Airline Picks as Fuel Volatility Challenges Sector
Investment firm Evercore ISI has identified its top airline stock selections, including Delta and United, as the industry navigates a combination of strong travel demand and extreme jet fuel price volatility.